• Explore /
  • Poster
  • / A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.

A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.

Abstract Poster

Authors

null

Krystal Pauline Cascetta

Icahn School of Medicine at Mount Sinai, New York, NY

Krystal Pauline Cascetta , Poulikos Poulikakos , Charles L. Shapiro , Aarti Sonia Bhardwaj , Julie Fasano , Hanna Irie , Paula Klein , Anupama Goel , Kevin Kalinsky , Sylvia Adams , Eleni Andreopoulou , Shabnam Jaffer , Meng Ru , Amy Tiersten

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT03304080

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS1103)

DOI

10.1200/JCO.2018.36.15_suppl.TPS1103

Abstract #

TPS1103

Poster Bd #

182b

Abstract Disclosures

Similar Posters

First Author: Erika Paige Hamilton

First Author: Mothaffar F. Rimawi

First Author: Nicholas Patrick McAndrew

First Author: Fabrice Andre